Glucaric acid

Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Glucaric acid?

Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Glucaric acid

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Brain Ischemia D002545 89 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Hyperlipidemias D006949 73 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Parkinson Disease D010300 53 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Precancerous Conditions D011230 48 associated lipids
Leukemia P388 D007941 43 associated lipids
Occupational Diseases D009784 42 associated lipids
Hypotension D007022 41 associated lipids
Adenoma D000236 40 associated lipids
Chemical and Drug Induced Liver Injury D056486 39 associated lipids
Heart Failure D006333 36 associated lipids
Epilepsy D004827 35 associated lipids
Hyperplasia D006965 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Micronuclei, Chromosome-Defective D048629 33 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Liver Diseases D008107 31 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Neoplasms D007680 29 associated lipids
Hyperinsulinism D006946 27 associated lipids
Alcoholism D000437 27 associated lipids
Myocardial Infarction D009203 21 associated lipids
Anemia D000740 21 associated lipids
Esophageal Neoplasms D004938 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Critical Illness D016638 13 associated lipids
Liver Diseases, Alcoholic D008108 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Carbon Tetrachloride Poisoning D002252 12 associated lipids
Hypocalcemia D006996 12 associated lipids
Iron Overload D019190 11 associated lipids
Per page 10 20 50 100 | Total 85

PubChem Associated disorders and diseases

What pathways are associated with Glucaric acid

Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Glucaric acid?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Glucaric acid?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Glucaric acid?

There are no associated biomedical information in the current reference collection.

What genes are associated with Glucaric acid?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Glucaric acid?

Knock-out

Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Glucaric acid

Download all related citations
Per page 10 20 50 100 | Total 1061
Authors Title Published Journal PubMed Link
Roth S et al. Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells. 2008 Transl Res pmid:18061126
Liu Z et al. Evaluating the protective role of ischaemic preconditioning in rat hearts using a stationary small-animal SPECT imager and 99mTc-glucarate. 2008 Nucl Med Commun pmid:18094633
pmid:18118003
Hasegawa K et al. [Improvement of urinary d-glucaric acid assay and its application]. 2008 Yakugaku Zasshi pmid:18176065
Wall GC and Pauly RA Evaluation of total-dose iron sucrose infusions in patients with iron deficiency anemia. 2008 Am J Health Syst Pharm pmid:18192261
Pai AB et al. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study. 2007 Clin Ther pmid:18201586
Al-Mueilo SH Beneficial effects of maintenance intravenous iron saccharate in hemodialysis patients. 2005 Apr-Jun Saudi J Kidney Dis Transpl pmid:18202490
Al-Saran KA and Sabry AA Pregnancy in dialysis patients: a case series. 2008 J Med Case Rep pmid:18205953
pmid:18208026
Zolezzi M Intravenous Iron Saccharate Complex: Guidelines for its use in the Management of Anemia of Renal Disease. 2003 Apr-Jun Saudi J Kidney Dis Transpl pmid:18209437
Souqiyyeh MZ and Shaheen FA Attitude of physicians towards iron supplementation in hemodialysis patients treated with erythropoietin. 2003 Apr-Jun Saudi J Kidney Dis Transpl pmid:18209438
Li H and Wang SX Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. 2008 Blood Purif. pmid:18212498
Jaber BL Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. 2008 Kidney Int. pmid:18235527
Bhatnagar R et al. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. 1991 Biochem. Pharmacol. pmid:1826840
Auerbach M and Al Talib K Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. 2008 Kidney Int. pmid:18274543
Earley CJ et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. 2009 Sleep Med. pmid:18280205
Li H and Wang SX Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. 2008 Mar-Apr Perit Dial Int pmid:18332450
Perek N et al. Could 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937. 2008 Eur. J. Nucl. Med. Mol. Imaging pmid:18338166
Lim R et al. A permanent tan from iron. 2008 Kidney Int. pmid:18340355
Auerbach M et al. The role of intravenous iron in anemia management and transfusion avoidance. 2008 Transfusion pmid:18346021
Aghaie A et al. New insights into the alternative D-glucarate degradation pathway. 2008 J. Biol. Chem. pmid:18364348
pmid:18384797
Usmanov RI et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. 2008 Mar-Apr J. Nephrol. pmid:18446719
Willerson JT Detection of acute myocardial infarcts by infarct-avid imaging. 1991 J. Nucl. Med. pmid:1846912
Hedenus M and Birgegård G The role of iron supplementation during epoietin treatment for cancer-related anemia. 2009 Med. Oncol. pmid:18473194
Kuo KL et al. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. 2008 J. Am. Soc. Nephrol. pmid:18495964
Picker SM et al. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. 2008 Transfusion pmid:18513255
pmid:18571185
Cuenca J et al. Efficacy of intravenous iron sucrose administration for correcting preoperative anemia in patients scheduled for major orthopedic surgery. 2008 Anesthesiology pmid:18580186
Auerbach M and Ballard H Intravenous iron in oncology. 2008 J Natl Compr Canc Netw pmid:18597712
Pinsk V et al. Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia. 2008 Isr. Med. Assoc. J. pmid:18605353
Kaplinsky C Parenteral iron therapy. 2008 Isr. Med. Assoc. J. pmid:18605363
Costa S et al. In vitro evaluation of the chemoprotective action mechanisms of leontopodic acid against aflatoxin B1 and deoxynivalenol-induced cell damage. 2009 J Appl Toxicol pmid:18636399
Anirban G et al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. 2008 Ren Fail pmid:18661414
Oleson L and Court MH Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases. 2008 J. Pharm. Pharmacol. pmid:18718121
pmid:18720044
pmid:18727354
Zółtaszek R et al. [The biological role of D-glucaric acid and its derivatives: potential use in medicine]. 2008 Postepy Hig Med Dosw (Online) pmid:18772850
Stefánsson BV et al. Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection. 2008 Free Radic. Biol. Med. pmid:18775775
pmid:18786076
Yang Z et al. Symbiosis between microorganisms from kombucha and kefir: Potential significance to the enhancement of kombucha function. 2010 Appl. Biochem. Biotechnol. pmid:18810658
pmid:18930421
Lord RS and Bralley JA Clinical applications of urinary organic acids. Part I: Detoxification markers. 2008 Altern Med Rev pmid:18950247
Young RS Determination of calcium oxide in calcined phosphate ores. 1973 Talanta pmid:18961359
Bolaños L et al. Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients. 2008 Adv Perit Dial pmid:18986009
Gonçalves P et al. The effect of high glucose on SERT, the human plasmalemmal serotonin transporter. 2008 Nutr Neurosci pmid:19000377
Yoon SH et al. Cloning and characterization of uronate dehydrogenases from two pseudomonads and Agrobacterium tumefaciens strain C58. 2009 J. Bacteriol. pmid:19060141
Moon TS et al. Production of glucaric acid from a synthetic pathway in recombinant Escherichia coli. 2009 Appl. Environ. Microbiol. pmid:19060162
pmid:19066859
Kell DB Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. 2009 BMC Med Genomics pmid:19133145
Ibrahim HN et al. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients. 2009 Clin J Am Soc Nephrol pmid:19211669
Haddad A et al. Use of iron sucrose in dialysis patients sensitive to iron dextran. 2009 Saudi J Kidney Dis Transpl pmid:19237805
Pollak VE et al. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. 2009 BMC Nephrol pmid:19245700
Torres-Corzo JG et al. Comparison of cerebrospinal fluid obtained by ventricular endoscopy and by lumbar puncture in patients with hydrocephalus secondary to neurocysticercosis. 2009 Surg Neurol pmid:19249584
Clark SF Iron deficiency anemia: diagnosis and management. 2009 Curr. Opin. Gastroenterol. pmid:19262200
Muñoz M et al. [Usefulness of the administration of intravenous iron sucrose for the correction of preoperative anemia in major surgery patients]. 2009 Med Clin (Barc) pmid:19264195
Vanin S et al. Seasonal variation of trehalose and glycerol concentrations in winter snow-active insects. 2008 Nov-Dec Cryo Letters pmid:19280052
Breborowicz A et al. Intravenous iron sucrose changes the intraperitoneal homeostasis. 2009 Blood Purif. pmid:19325240
Lindgren S et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. 2009 Scand. J. Gastroenterol. pmid:19330567
Kim YH et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. 2009 Acta Haematol. pmid:19332985
Zanor MI et al. Metabolic characterization of loci affecting sensory attributes in tomato allows an assessment of the influence of the levels of primary metabolites and volatile organic contents. 2009 J. Exp. Bot. pmid:19346240
Gorder V et al. Treatment of restless legs syndrome with iron infusion therapy. 2009 JAAPA pmid:19354112
Nakamura Y et al. Decreased valproate level caused by VPA-glucuronidase inhibition by carbapenem antibiotics. 2008 Drug Metab Lett pmid:19356106
De Saint-Hubert M et al. Molecular imaging of cell death. 2009 Methods pmid:19362149
pmid:19379368
Bencaiova G et al. Iron prophylaxis in pregnancy: intravenous route versus oral route. 2009 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:19406557
pmid:19432851
Luo Z et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. 2009 Endocrine pmid:19440859
pmid:19481054
Grote L et al. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. 2009 Mov. Disord. pmid:19489063
Kulnigg S et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. 2009 Am. J. Gastroenterol. pmid:19491860
Asma S et al. Safety, therapeutic effectiveness, and cost of parenteral iron therapy. 2009 Int. J. Hematol. pmid:19495930
García-Erce JA et al. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. 2009 Vox Sang. pmid:19497085
Nguyen TV Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. 2009 Am J Health Syst Pharm pmid:19498125
Fontés G et al. Involvement of Per-Arnt-Sim Kinase and extracellular-regulated kinases-1/2 in palmitate inhibition of insulin gene expression in pancreatic beta-cells. 2009 Diabetes pmid:19502418
Krafft A et al. Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose alone. 2009 Fetal. Diagn. Ther. pmid:19506383
Toblli JE et al. Differences between original intravenous iron sucrose and iron sucrose similar preparations. 2009 Arzneimittelforschung pmid:19517894
Shimizu Y et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. 2009 Bone pmid:19555782
Li H and Wang SX [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study]. 2009 Zhonghua Yi Xue Za Zhi pmid:19567093
Yi CX et al. A major role for perifornical orexin neurons in the control of glucose metabolism in rats. 2009 Diabetes pmid:19592616
Barraclough KA et al. Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). 2009 BMC Nephrol pmid:19635169
Dueber JE et al. Synthetic protein scaffolds provide modular control over metabolic flux. 2009 Nat. Biotechnol. pmid:19648908
Dong T and Schellhorn HE Global effect of RpoS on gene expression in pathogenic Escherichia coli O157:H7 strain EDL933. 2009 BMC Genomics pmid:19650909
DeLisa MP and Conrado RJ Synthetic metabolic pipelines. 2009 Nat. Biotechnol. pmid:19668178
pmid:19717754
Edwards TJ et al. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. 2009 Br J Surg pmid:19731228
Gehret TC et al. Convenient large-scale synthesis of D-glucaro-1,4:6,3-dilactone. 2009 J. Org. Chem. pmid:19777999
Muñoz M et al. Intravenous iron in inflammatory bowel disease. 2009 World J. Gastroenterol. pmid:19787830
Smith TG et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. 2009 JAMA pmid:19809026
Comín-Colet J et al. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. 2009 J. Card. Fail. pmid:19879457
Ball LM et al. Formation of mutagenic urinary metabolites from 1-nitropyrene in germ-free and conventional rats: role of the gut flora. 1991 Carcinogenesis pmid:1988167
McMahon LP et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. 2010 Nephrol. Dial. Transplant. pmid:19906658
Orlandi C et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. 1991 J. Nucl. Med. pmid:1992031
Morimoto S et al. Significance of urinary glucaric acid measurement and its application to paclitaxel therapy. 2009 Gan To Kagaku Ryoho pmid:19920388
Gambini JP et al. Evaluation of patients with head and neck cancer by means of 99mTc-glucarate. 2009 J Nucl Med Technol pmid:19949020
Stancu S et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? 2010 Clin J Am Soc Nephrol pmid:20019121
Sienkiewicz-Porzucek A et al. Mild reductions in mitochondrial NAD-dependent isocitrate dehydrogenase activity result in altered nitrate assimilation and pigmentation but do not impact growth. 2010 Mol Plant pmid:20035036
Fior S and Gerola PD Impact of ubiquitous inhibitors on the GUS gene reporter system: evidence from the model plants Arabidopsis, tobacco and rice and correction methods for quantitative assays of transgenic and endogenous GUS. 2009 Plant Methods pmid:20042078
Ginsberg G and Rice DC Does rapid metabolism ensure negligible risk from bisphenol A? 2009 Environ. Health Perspect. pmid:20049111
Dangsuwan P and Manchana T Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. 2010 Gynecol. Oncol. pmid:20051288